Description
COVID-19 has a major impact on all medical disciplines, among them hepatology. The new vaccines have potential to finally solve this global health crisis. This webinar will dive into different issues related to COVID-19 vaccination including the relative risk for severe COVID-19 in patients with chronic liver diseases (cirrhosis, metabolic and autoimmune liver disease, liver transplantation) as compared to other high-risk populations (e.g. old age), the efficacy and safety of current COVID-19 vaccines (mRNA vaccines, vector vaccines), their contraindications and limitations in patients with liver diseases.
The scientific rationale for currently recommended vaccination strategies concerning patients with liver disease will also be discussed, as well as the first outcome data of population-based vaccination in patients with and without liver diseases.
The webinar will take place on 9 March, from 18:00 to 19:30 CET
Why attend
Programme
| Time | Title |
| 18:00-18:02 | Welcome & Introduction Ulrich Beuers, Amsterdam University Medical Centers Verena Keitel, Universitätsklinikum Düsseldorf |
| 18:02-18:17 | Defining liver patients in urgent need of a COVID-19 vaccine for priorisation Thomas Marjot, University of Oxford, United Kingdom |
| 18:17-18:32 | Overview over the COVID-19 vaccines available in Europe Julian Schulze-zur-Wiesch, University Medical Center Hamburg-Eppendorf, Germany |
| 18:32-18:47 | Benefit/risk of COVID-19 vaccinations: what do we know to date and how can it translate to specific populations? Miriam Sturkenboom, Julius Center Research Program Cardiovascular Epidemiology, Utrecht, Netherlands |
| 18:47-19:02 | First practical experiences with COVID-19 vaccination in Israeli patients with liver disease Rifaat Safadi, Hadassah Medical Centers of the Hebrew, University Jerusalem, Israel |
| 19:02-19:30 | Discussion and Q&A All |
Target audience
- Hepatologists, gastroenterologists
- General practitioners
- Health care professionals
- Clinical scientists
- Basic scientists
CME credits
COVID19 vaccination in patients with liver disease webinar online, Switzerland, 09/03/2021-09/03/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 1 European CME credits (ECMEC®s).
Each medical specialist should claim only those credits that he/she actually spent in the educational activity.
Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.